Most cost-benefit analyses of clinical technology focus on what you stop paying for. A joint study from CluePoints and Tufts Center for the Study of Drug Development flips that logic: in a modeled Phase III oncology trial, 84% of RBQM’s $13.8 million net financial value came from time savings, not from cutting monitoring costs, which contributed just 16%. That split matters because sponsors building internal investment cases for RBQM typically lead with the monitoring cost reduction story, which is the smaller number by a wide margin.
The mechanism is straightforward. Phase III programs that implemented RBQM saw clinical phase durations shrink by up to 19%. For a late-stage oncology asset, even weeks off the development clock translate to earlier market entry and longer effective patent life, so the financial leverage sits almost entirely there rather than in site visit budgets. The eNPV framework, originally applied to decentralized trial models, makes that conversion explicit: time saved in Phase III compounds forward into revenue, while a cheaper monitoring visit stays a cheaper monitoring visit.
CluePoints and Tufts CSDD’s Abigail Dirks walked through the model in a video interview published this week, with CluePoints’ Sylviane de Viron. The conversation is partly a framing exercise: if a sponsor’s procurement team evaluates RBQM as a cost-reduction tool, the 16% monitoring savings figure is the only one that registers, and the investment looks modest. Positioned through eNPV and development timeline, the same tool looks different to a CFO or portfolio team weighing when a Phase III asset reaches launch. FDA’s 2023 risk-based monitoring guidance has already established the regulatory basis for these approaches, so the remaining friction is largely internal: getting the right stakeholders to evaluate RBQM against the right metric.
For clinical operations teams trying to move budget conversations, the practical implication is that the Phase III oncology numbers give them a defensible, peer-reviewed anchor. Whether a specific program replicates that 84/16 split depends on trial complexity and therapeutic area, but the directional argument holds: the case for RBQM investment is strongest when cycle time reduction, not site monitoring spend, is the denominator the finance team is watching.
Source link: https://cluepoints.com/why-time-savings-is-the-largest-driver-of-rbqms-financial-value/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
